Review and Feature Article
Adverse Events and Safety of SARS-CoV-2 Vaccines: What’s New and What’s Next

https://doi.org/10.1016/j.jaip.2022.04.035Get rights and content

Just over 1 year following rollout of the first vaccines for coronavirus disease 2019, 572 million doses have been administered in the United States. Compared with the number of vaccines administered, adverse effects such as anaphylaxis have been rare, and seemingly, the more serious the effect, the rarer the occurrence. Despite these adverse effects, there are few, if any, true contraindications to coronavirus disease 2019 vaccination and most individuals recover without further sequelae. This review provides guidance for the allergist/immunologist regarding appropriate next steps based on patient’s known allergy history or adverse reaction after receipt of coronavirus disease 2019 vaccine to assist in safe global immunization.

Key words

COVID-19
vaccines
anaphylaxis
allergic reaction
adverse effects

Abbreviations used

CDC
Centers for Disease Control and Prevention
COVID-19
coronavirus disease 2019
LAD
lymphadenopathy
mRNA
messenger RNA
PEG
polyethylene glycol
SARS-CoV-2
severe acute respiratory syndrome coronavirus 2
VITT
vaccine-induced immune-mediated thrombosis and thrombocytopenia
VZV
varicella zoster virus

Cited by (0)

E.J.P. reports grants from the National Institutes of Health (grant nos. P50GM115305, R01HG010863, R01AI152183, R21AI139021, and U01AI154659) and from the National Health and Medical Research Council of Australia. Funders played no role in any aspect of this review.

Conflicts of interest: E. J. Phillips reports grants from the National Institutes of Health (grant nos. P50GM115305, R01HG010863, R01AI152183, R21AI139021, and U01AI154659) and from the National Health and Medical Research Council of Australia; reports royalties from UpToDate and consulting fees from Janssen, Vertex, Biocryst, and Regeneron; is codirector of IIID Pty Ltd, which holds a patent for HLA- B57:01 testing for abacavir hypersensitivity; and has a patent pending for Detection of Human Leukocyte Antigen-A32:01 in connection with Diagnosing Drug Reaction with Eosinophilia and Systemic Symptoms without any financial remuneration and not directly related to the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.

The case described in this review is a representative patient based on experiences in our outpatient clinic and does not correspond to an actual patient.

View Abstract